These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 15229972)

  • 1. Extraarticular rheumatoid arthritis and drug-induced syndromes: understanding the role of tumor necrosis factor inhibitors.
    Bruyn GA
    J Rheumatol; 2004 Jul; 31(7):1461; author reply 1462. PubMed ID: 15229972
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
    Guillevin L; Mouthon L
    J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
    [No Abstract]   [Full Text] [Related]  

  • 3. New drugs for rheumatoid arthritis.
    Olsen NJ; Stein CM
    N Engl J Med; 2004 May; 350(21):2167-79. PubMed ID: 15152062
    [No Abstract]   [Full Text] [Related]  

  • 4. Induction of antinuclear antibodies in patients with rheumatoid arthritis treated with infliximab and leflunomide.
    Bingham SJ; Buch MH; Kerr MA; Emery P; Valadäo Barcelos AT
    Arthritis Rheum; 2004 Dec; 50(12):4072-3. PubMed ID: 15593202
    [No Abstract]   [Full Text] [Related]  

  • 5. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series.
    Jarrett SJ; Cunnane G; Conaghan PG; Bingham SJ; Buch MH; Quinn MA; Emery P
    J Rheumatol; 2003 Oct; 30(10):2287-91. PubMed ID: 14528531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of myeloperoxidase-antineutrophil cytoplasmic antibody-associated renal vasculitis in a patient receiving treatment with anti-tumor necrosis factor-α.
    Hirohama D; Hoshino J; Hasegawa E; Yamanouchi M; Hayami N; Suwabe T; Sawa N; Takemoto F; Ubara Y; Hara S; Ohashi K; Takaichi K
    Mod Rheumatol; 2010 Dec; 20(6):602-5. PubMed ID: 20680377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous vasculitis induced by TNF inhibitors: a report of three cases.
    Fujikawa K; Kawakami A; Hayashi T; Iwamoto N; Kawashiri SY; Aramaki T; Ichinose K; Tamai M; Arima K; Kamachi M; Yamasaki S; Nakamura H; Ida H; Origuchi T; Eguchi K
    Mod Rheumatol; 2010 Feb; 20(1):86-9. PubMed ID: 19812889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymyositis associated with infliximab treatment for rheumatoid arthritis.
    Urata Y; Wakai Y; Kowatari K; Nitobe T; Mizushima Y
    Mod Rheumatol; 2006; 16(6):410-1. PubMed ID: 17165006
    [No Abstract]   [Full Text] [Related]  

  • 9. Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study.
    Kiely PD; Johnson DM
    Rheumatology (Oxford); 2002 Jun; 41(6):631-7. PubMed ID: 12048288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ANCA-associated renal vasculitis following anti-tumor necrosis factor alpha therapy.
    Simms R; Kipgen D; Dahill S; Marshall D; Rodger RS
    Am J Kidney Dis; 2008 Mar; 51(3):e11-4. PubMed ID: 18295046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pneumonitis caused by Legionella pneumoniae in a patient with rheumatoid arthritis treated with anti-TNF-alpha therapy (infliximab).
    Li Gobbi F; Benucci M; Del Rosso A
    J Clin Rheumatol; 2005 Apr; 11(2):119-20. PubMed ID: 16357717
    [No Abstract]   [Full Text] [Related]  

  • 12. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Costenbader KH; Glass R; Cui J; Shadick N
    JAMA; 2006 Nov; 296(18):2201; author reply 2203-4. PubMed ID: 17090761
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Callegari PE; Schaible TF; Boscia JA
    JAMA; 2006 Nov; 296(18):2202; author reply 2203-4. PubMed ID: 17090762
    [No Abstract]   [Full Text] [Related]  

  • 14. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Hochman D; Wolff B
    JAMA; 2006 Nov; 296(18):2203; author reply 2203-4. PubMed ID: 17090763
    [No Abstract]   [Full Text] [Related]  

  • 15. Severe Parkinson's disease in rheumatoid arthritis patient treated with infliximab.
    Hrycaj P; Korczowska I; Łacki JK
    Rheumatology (Oxford); 2003 May; 42(5):702-3. PubMed ID: 12709557
    [No Abstract]   [Full Text] [Related]  

  • 16. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
    Chan CY; Browning JC; Larsen F; Hsu S
    Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis.
    Richette P; Dieudé P; Damiano J; Lioté F; Orcel P; Bardin T
    J Rheumatol; 2004 Oct; 31(10):2079-81. PubMed ID: 15468380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level.
    van Rijthoven AW; Bijlsma JW; Canninga-van Dijk M; Derksen RH; van Roon JA
    Rheumatology (Oxford); 2006 Oct; 45(10):1317-9. PubMed ID: 16844698
    [No Abstract]   [Full Text] [Related]  

  • 19. Reactivation of brucellosis after treatment with infliximab in a patient with rheumatoid arthritis.
    Jiménez FG; Colmenero JD; Irigoyen MV
    J Infect; 2005 May; 50(4):370-1. PubMed ID: 15845443
    [No Abstract]   [Full Text] [Related]  

  • 20. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis.
    Okada SK; Siegel JN
    JAMA; 2006 Nov; 296(18):2201-2; author reply 2203-4. PubMed ID: 17090760
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.